Refine
Has Fulltext
- yes (2)
Is part of the Bibliography
- yes (2)
Year of publication
- 2019 (2) (remove)
Document Type
- Doctoral Thesis (2)
Language
- English (2)
Keywords
- Muscarinrezeptor (2) (remove)
G protein-coupled receptor research looks out for new technologies to elucidate the complex
processes of receptor activation, function and downstream signaling with spatiotemporal
resolution, preferably in living cells and organisms. A thriving approach consists in making use
of the unsurpassed properties of light, including its high precision in space and time, noninvasiveness
and high degree of orthogonality regarding biological processes. This is realized
by the incorporation of molecular photoswitches, which are able to effectively respond to light,
such as azobenzene, into the structure of a ligand of a given receptor. The muscarinic
acetylcholine receptors belong to class A GPCRs and have received special attention in this
regard due to their role as a prototypic pharmacological system and their therapeutic potential.
They mediate the excitatory and inhibitory effects of the neurotransmitter acetylcholine and
thus regulate diverse important biological processes, especially many neurological functions in
our brain.
In this work, the application of photopharmacological tool compounds to muscarinic receptors
is presented, consisting of pharmacophores extended with azobenzene as light-responsive
motif. Making use of the dualsteric concept, such photochromic ligands can be designed to bind
concomitantly to the orthosteric and allosteric binding site of the receptor, which is
demonstrated for BQCAAI (M1) and PAI (M2) and may lead to subtype- and functionalselective
photoswitchable ligands, suitable for further ex vivo and in vivo studies.
Moreover, photoswitchable ligands based on the synthetic agonist iperoxo were investigated
extensively with regard to their photochemical behavior and pharmacological profile, outlining
the advantages and challenges of using red-shifted molecular photoswitches, such as tetraortho-
fluoro azobenzene. For the first time on a GPCR it was examined, which impact the
different substitution pattern has on both the binding and the activity on the M1 receptor. Results
show that substituted azobenzenes in photopharmacological compounds (F4-photoiperoxo and
F4-iper-azo-iper) not just represent analogs with other photophysical properties but can exhibit
a considerably different biological profile that has to be investigated carefully.
The achievements gained in this study can give important new insights into the binding mode
and time course of activation processes, enabling precise spatial and temporal resolution of the
complex signaling pathway of muscarinic receptors. Due to their role as exemplary model
system, these findings may be useful for the investigation into other therapeutically relevant
GPCRs.
GPCRs, particularly muscarinic receptors (mAChRs), are significant therapeutic targets in many physiological conditions. The significance of dualsteric hybrids selectively targeting mAChR subtypes is their great advantage in avoiding undesired side effects. This is attained by exploitation of the high affinity of ligand-binding to the orthosteric site and the structural diversity of the allosteric site to target an individual mAChR subtype, as well as offering signal bias to avoiding undesired transduction pathways. Furthermore, dualsteric targeting of mAChR subtypes helps in the elucidation of the physiological role of each individual mAChR subtype.
The first project was the attempt of synthesis of the M2-preferring ligand AFDX-384. AFDX-384 is known to preferentially bind to the M2 receptor subtype as an orthosteric antagonist, with partial interaction with residues in the allosteric site. This project aimed to re-trace the synthesis route of AFDX-384, to open the door to its upscaling and the future synthesis of AFDX-type dualsteric ligands. The multi-step synthesis of AFDX-384 is achieved through the synthesis of its 2 precursors, the chloro acyl derivative VIII and the piperidinyl derivative IV. Upscaled synthesis of the piperidinyl derivative IV was attained. Synthesis of the chloro acyl compound VIII was attempted. Several trials to synthesize the benzopyridodiazepine nucleus as well as its chloro-acylation resulted in the production of the novel crystal structures V and VI. X-ray crystallography was also done for crystallized molecules of the closed-ring benzopyridodiazepine VII that was previously synthesized. Chloro-acylation reactions of compound VII using phosgene seem to be attainable when done using reflux overnight. However, the use of methanol to aid in elution during silica gel column chromatography converted the expected product to the carbamate analogue IX. Hence, further attempts in purification should refrain from the use of methanol. The use of triphosgene instead of phosgene demonstrates a cleaner route for further upscaled synthesis.
The second project was the synthesis of dualsteric ligands involving variable orthosteric and allosteric moieties. Four different types of hybrids have been created over multiple steps. Dualsteric ligands have been synthesized using either a phthalimido- or 1,8-naphthalimidopropylamino moiety as the allosteric-binding group, coupled to either N-desmethyl pirenzepine or N-desmethyl clozapine using variable chain lengths. Furthermore, the synthesis of the dualsteric ligands involving N-desmethyl clozapine linked to either the super-agonist iperoxo or acetylcholine, and being connected using variable alkane chain lengths. Several reaction conditions have been investigated throughout the analysis of the optimal condition to conduct the critical final step of synthesis of these dualsteric hybrids, which involves the linking of the two segments of the hybrid together. The optimal method, which produced the least side products and highest yield, was to connect the two intermediates of the compound in absence of base, catalyst or microwaves while stirring at 35 °C for several days using acetonitrile as solvent (silica gel TLC monitoring, 0.2 M aqueous KNO3/MeOH 2:3). The ideal purification methods for the final compounds were found to be either crystallization from the reaction medium or using C18 reverse phase silica gel flash chromatography (using H2O/MeOH solvent system). All the hybrids will be subjected to pharmacological testing using the appropriate FRET assays.